Pharmaceutical companies between 1-30 billions dollars capitalization:
- Alkermes
- Ionis Pharmaceuticals
- Incyte Corporation
- Sarepta Therapeutics
- Blueprint Medicines
- Alnylam Pharmaceuticals
- BioCryst Pharmaceuticals
- Ultragenyx Pharmaceutical
- Krystal Biotech
- ACADIA Pharmaceuticals
- Adamas Pharmaceuticals
- Aimmune Therapeutics
- Arcus Biosciences
- Alector
- Arena Pharmaceuticals
- Arvinas
- Axovant Gene Therapies
- BeiGene
- BioMarin Pharmaceutical
- Cytokinetics
- Deciphera Pharmaceuticals
- Denali Therapeutics
- Dicerna Pharmaceuticals
- Exact Sciences
- Exelixis
- FibroGen
- Fate Therapeutics
- Global Blood Therapeutics
- Halozyme Therapeutics,
- ImmunoGen
- Intercept Pharmaceuticals
- Intellia Therapeutics
- Ironwood Pharmaceuticals
- Karyopharm Therapeutics
- Kodiak Sciences
- MacroGenics
- Madrigal Pharmaceuticals
- Mirati Therapeutics
- Momenta Pharmaceuticals
- NantKwest
- NextCure
- Novavax
- Protagonist Therapeutics
- Prothena
- Puma Biotechnology
- REGENXBIO
- Revance Therapeutics
- Rubius Therapeutics
- Sorrento Therapeutics
- T.G. Therapeutics
- Immunovant
- Atara Biotherapeutics
- Cellectis
- Sutro Biopharma
- Cerevel Therapeutics
- Amicus Therapeutics
- AnaptysBio
- C4 Therapeutics
- Gossamer Bio
- Kiniksa Pharmaceuticals
- MacroGenics
- Omeros Corporation
- Travere Therapeutics
- Zymeworks
- Agenus
- Molecular Partners
- Unity Biotechnology
- Calithera Biosciences
- Apellis Pharmaceuticals
- Allogene Therapeutics
- Alder Biopharmaceuticals
- Aimmune Therapeutics
- Amphastar Pharmaceuticals
- Anika Therapeutics
- ARMO Biosciences
- Arrowhead Pharmaceuticals
- Atara Biotherapeutics
- Aurinia Pharmaceuticals
- AVEO Pharmaceuticals
- BioDelivery Sciences International
- BioLineRx
- Cara Therapeutics
- Celldex Therapeutics
- Chemocentryx
- Chiasma
- Clovis Oncology
- Corvus Pharmaceuticals
- CureVac
- CytomX Therapeutics
- Eiger BioPharmaceuticals
- Epizyme
- Galectin Therapeutics
- Genmab
- Homology Medicines
- Inozyme Pharma
- KalVista Pharmaceuticals
- Magenta Therapeutics
- MannKind Corporation,
- MEI Pharma,
- Mersana Therapeutics,
- Myovant Sciences,
- NextCure,
- Novus Therapeutics,
- Odonate Therapeutics,
- Oncorus,
- Organogenesis Holdings,
- Palatin Technologies,
- Pieris Pharmaceuticals,
- Rain Therapeutics,
- Relay Therapeutics,
- Rocket Pharmaceuticals,
- Sana Biotechnology,
- Selecta Biosciences,
- Seres Therapeutics,
- Sierra Oncology,
- Surface Oncology,
- TCR2 Therapeutics,
- Tiziana Life Sciences,
- Trillium Therapeutics,
- Verastem Oncology,
- Xencor,
- XOMA Corporation,
- Y-mAbs Therapeutics,
- Abeona Therapeutics,
- Affimed Therapeutics,
- Aptevo Therapeutics,
- Arcturus Therapeutics,
- Arvinas,
- Atreca,
- BioXcel Therapeutics,
- Caladrius Biosciences,
- Century Therapeutics,
- Checkmate Pharmaceuticals,
- Cue Biopharma,
- Denali Therapeutics,
- Evelo Biosciences,
- Galera Therapeutics,
- Harpoon Therapeutics,
- Imago BioSciences,
- Instil Bio,
- Iovance Biotherapeutics,
- Lyell Immunopharma,
- NGM Biopharmaceuticals,
- Pliant Therapeutics,
- Provention Bio,
- Rain Therapeutics,
- TScan Therapeutics and
- Viridian Therapeutics.
Pharmaceutical companies below 1 billion dollars capitalization:
- Alkermes,
- BioMarin Pharmaceutical
- Jazz Pharmaceuticals
- Horizon Therapeutics
- Exact Sciences
- Incyte Corporation,
- Neurocrine Biosciences
- Seagen Inc.
- Vertex Pharmaceuticals
- Ionis Pharmaceuticals,
- Sarepta Therapeutics,
- Blueprint Medicines,
- Alnylam Pharmaceuticals,
- Ultragenyx Pharmaceutical,
- BeiGene,
- Intercept Pharmaceuticals,
- Exelixis,
- Global Blood Therapeutics,
- Dicerna Pharmaceuticals,
- Arcus Biosciences,
- Alector,
- Deciphera Pharmaceuticals,
- Revance Therapeutics,
- FibroGen,
- Arena Pharmaceuticals
- ACADIA Pharmaceuticals
- Halozyme Therapeutics
- Mirati Therapeutics
- ImmunoGen
- Madrigal Pharmaceuticals,
- Travere Therapeutics,
- Kodiak Sciences,
- Cytokinetics
- REGENXBIO,
- Prothena,
- Arvinas,
- Aldeyra Therapeutics,
- Puma Biotechnology,
- Immunovant,
- Apellis Pharmaceuticals
- NextCure
- Zymeworks
- Atara Biotherapeutics
- Omeros Corporation
- TG Therapeutics
- MacroGenics
- Karyopharm Therapeutics
- Rubius Therapeutics
- Agenus
- Evelo Biosciences
Leading competitors of AstraZeneca (based on capitalization)
- Johnson & Johnson (400-500 billion)
- Roche Holding AG (250-300 billion)
- Merck & Co. (260-280 billion)
- Novartis AG (200-250 billion)
- Pfizer (200 billion U.S.)
- AstraZeneca (190 billion)
- Sanofi S.A. (160-180 billion)
- Amgen Inc. (120-140 billion)
- Bristol-Myers Squibb Co. (120-140 billion)
- GSK PLC. (60-80 billion)
- Moderna (40-50 billion)
- Bayer AG* (45-50 billion)
- Biogen Inc. (40-55 billion)
*Bayer AG is not a usual competitor of AstraZeneca, and neither is Johnson & Johnson.
Johnson & Johnson (J&J)
Johnson & Johnson sells medical devices, competing with Medtronic and Siemens Healthineers. It has a 35% market share overall, but Medtronic is surpassing it by a few percent.
Medtronic is 3% higher than Johnson & Johnson (by market share), while Johnson & Johnson is 3% higher than Siemmens Heathineers.
Johnson & Johnson sells medical devices, which account for 28% of its profits.
The consumer health products division produces 17% of its revenue, but the two divisions total only 45%.
Bayer AG (XETR: BAYGN)
However, when Bayer AG acquired Monsanto, it accounted for almost 50% of its operations.
Its “Monsanto division” is more inclined to chemical production. This division faces significant players from the “agriscience” division of Corteva (NYSE: CTVA), Syngenta (unlisted – state own by China), and BASF (XETRA: BAS).

Disclaimer
The companies mentioned above are not trading advice or companies to invest in.
The purpose of enlisting them is only informative.